Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

107.68
-0.4950-0.46%
Volume:19.64K
Turnover:2.12M
Market Cap:12.22B
PE:31.84
High:108.25
Open:108.08
Low:107.68
Close:108.17
52wk High:108.49
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:4.06
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:85.14
PE(LYR):42.06

Loading ...

Halozyme Announces Global Collaboration and License Agreement With GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

THOMSON REUTERS
·
May 07

Halozyme, Oruka sign global license to develop ORKA-001 using Hypercon technology

Reuters
·
May 06

Halozyme Therapeutics Inc - Oruka to Make Upfront and Milestone Payments; Halozyme Eligible for Mid-Single Digit Royalties

THOMSON REUTERS
·
May 06

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop Orka-001 With Hypercon™ Technology

THOMSON REUTERS
·
May 06

Exports Triple in Six Years, HALO Value Reassessment: Huatai-PB Engineering Machinery ETF Launches on May 6

Deep News
·
May 06

Halozyme Director Bernadette Connaughton sells 1,625 shares worth $103,155.00

Reuters
·
May 06

Earning Preview: Halozyme Therapeutics this quarter’s revenue is expected to increase by 55.99%, and institutional views are bullish

Earnings Agent
·
May 05

Halozyme to report first-quarter results after market close May 11

Reuters
·
May 01

Johnson & Johnson names Ryan Koors vice president of investor relations

Reuters
·
Apr 30

Halozyme appoints Darren Snellgrove CFO, effective June 8

Reuters
·
Apr 30

Halozyme Appoints Darren Snellgrove as Chief Financial Officer

THOMSON REUTERS
·
Apr 30

Halozyme Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 29

Halozyme bylaws allow majority shareholders to remove directors without cause

Reuters
·
Apr 25

Top Performing Mutual Funds' Q1 Portfolio Adjustments Highlight AI and HALO Assets

Deep News
·
Apr 23

Nexalin Advances Pivotal Insomnia Trial for HALO Clarity

TIPRANKS
·
Apr 23

Nexalin Technology enters agreements to advance HALO Clarity trial

TIPRANKS
·
Apr 22

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

GlobeNewswire
·
Apr 22

Halozyme price target raised to $96 from $94 at Morgan Stanley

TIPRANKS
·
Apr 21

Investment Focus on Tech Innovation and HALO Assets Becomes Clearer This Year

Deep News
·
Apr 20

HALO Trading: Fleeting Trend or Enduring Investment Strategy?

Deep News
·
Apr 18